Core Insights - Evofem Biosciences reported a 10% increase in net sales for Q3 2025, reaching $5.0 million compared to $4.5 million in the same quarter last year, driven by effective sales strategies and marketing initiatives [2][11] - The company achieved operating income of $1.0 million in Q3 2025, a significant improvement from a loss of $2.4 million in the prior year quarter [4][11] - Total operating expenses decreased by 42% to $4.0 million in Q3 2025 from $6.9 million in the same period last year, primarily due to reduced general and administrative costs and a one-time accounting gain [3][11] Financial Performance - Net loss attributable to common stockholders was $1.7 million in Q3 2025, an improvement from a net loss of $2.4 million in Q3 2024, translating to a loss of $0.01 per share compared to $0.02 per share in the prior year [5][15] - The company had restricted cash of $0.8 million as of September 30, 2025, up from $0.7 million at the end of 2024 [6] Product and Market Developments - Evofem is advancing strategies to reduce manufacturing costs by approximately 50% for its products PHEXX and SOLOSEC, which is expected to enhance profitability and facilitate entry into price-sensitive global markets [11] - SOLOSEC has been submitted for marketing approval in the United Arab Emirates under a licensing agreement, indicating ongoing expansion efforts [11] - Patient recruitment is ongoing for a Phase 4 clinical trial evaluating SOLOSEC's effectiveness compared to metronidazole for treating Trichomonas vaginalis, with promising hypotheses regarding cost-effectiveness [11] Corporate Actions - Following a Special Meeting of Stockholders on October 20, 2025, Evofem terminated its merger agreement with Aditxt after stockholders did not approve the transaction [11]